ERBB4 inhibitors and methods of use thereof
US10045990B2 · kind B2 · utility
11Cited by
2References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 2, 2016 |
| Grant date | Aug 14, 2018 |
| Priority date | — |
| Expiry date | Mar 2, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/517
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods of treating diseases that exhibit over-activation of the ERBB4 pathway, such as breast cancer and lung cancer. The method comprises administering to a subject having a disease that exhibits over-activation of the ERBB4 pathway and a gene expression profile consistent with an ERBB4-sensitive profile a therapeutically effective amount of an ERBB4 inhibitor, wherein the disease is effectively treated. Gene expression profiles of ERBB4-sensitive cells and microarrays suitable for protein-tyrosine kinases are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.